<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605071</url>
  </required_header>
  <id_info>
    <org_study_id>11-0788</org_study_id>
    <secondary_id>R01DK088105</secondary_id>
    <nct_id>NCT01605071</nct_id>
  </id_info>
  <brief_title>Timing Estrogen After MenoPaUSe</brief_title>
  <acronym>TEMPUS</acronym>
  <official_title>Time Past Menopause, Duration of Estrogen Deficiency, and Insulin Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to test whether the effect of estrogen on insulin metabolism&#xD;
      depends on the timing of treatment relative to when a woman went through menopause. The&#xD;
      investigators hypothesize that estrogen will improve insulin sensitivity in early&#xD;
      postmenopausal women, but decrease insulin sensitivity in late postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large clinical trials have shown a reduced incidence of type 2 diabetes in postmenopausal&#xD;
      women randomized to estrogen-based hormone therapy compared to placebo. Moreover, studies&#xD;
      suggest development of diabetes is reduced in postmenopausal women who used hormone therapy&#xD;
      for a part of the postmenopausal period compared to women who never used hormone therapy.&#xD;
      Consistent with this, our preliminary data suggest that the timing of estrogen treatment&#xD;
      relative to the menopause may be an important determinant of whether there are favorable&#xD;
      effects on insulin action. Our observations suggest that estrogen improves insulin&#xD;
      sensitivity in early postmenopausal women, but may decrease insulin sensitivity in those more&#xD;
      than 10 years past menopause. More and more studies suggest estrogens have divergent effects&#xD;
      on cardiovascular risk when initiated close to the onset of menopause rather than distant&#xD;
      from the menopause; we hypothesize this is also true for diabetes risk. The goal of this&#xD;
      study is to determine whether the effects of estrogen on insulin metabolism are different in&#xD;
      women who are early postmenopausal compared to late postmenopausal. To meet our goal, we&#xD;
      propose to measure insulin sensitivity in women who are within 6 years of the onset of&#xD;
      menopause or more than 10 years beyond the menopause and who have not used hormone therapy&#xD;
      previously. All women will be studied on two separate occasions, one day with and one day&#xD;
      without short-term (1 week) treatment with transdermal estradiol. We expect that estradiol&#xD;
      will increase insulin sensitivity in early postmenopausal women and decrease insulin&#xD;
      sensitivity in late postmenopausal women. We also expect that estrogen receptors in fat and&#xD;
      muscle may change with increasing time after menopause. Thus, we will collect fat and muscle&#xD;
      biopsies to compare changes in estrogen receptors between early and late postmenopausal women&#xD;
      and in response to 1 week of estradiol treatment. We believe these studies will provide&#xD;
      evidence for a benefit of estradiol on insulin sensitivity when administered early, but not&#xD;
      late, after menopause; likely contributing to delayed onset of type 2 diabetes in&#xD;
      postmenopausal women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp)</measure>
    <time_frame>after 1wk estradiol or placebo</time_frame>
    <description>Estrogen mediated change in glucose disposal rate and time since menopause&#xD;
Baseline GDR (no difference between groups)&#xD;
E2 mediated change (significant difference between groups)&#xD;
randomized order of testing, cross-over design</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skeletal Muscle Estrogen Receptor Expression</measure>
    <time_frame>after 1wk estradiol or placebo</time_frame>
    <description>Estrogen receptors (ERα and ERβ) differences in time since menopause and estrogen treatment&#xD;
randomized order of testing, cross-over design</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Muscle Estrogen Receptor Expression (Protein/Cyto Protein)</measure>
    <time_frame>after 1wk estradiol or placebo</time_frame>
    <description>Estrogen receptors (ERα and ERβ) differences in time since menopause and estrogen treatment&#xD;
randomized order of testing, cross-over design</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Estrogen Receptor Expression</measure>
    <time_frame>Baseline</time_frame>
    <description>Adipose tissue estrogen receptor expression associated with age and menopause&#xD;
Abdominal and femoral subcutaneous adipose tissue ERα and ERβ expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose Tissue Estrogen Receptor Expression (ERα:ERβ)</measure>
    <time_frame>Baseline</time_frame>
    <description>Adipose tissue estrogen receptor expression associated with age and menopause&#xD;
Abdominal and femoral subcutaneous adipose tissue ratio of ERα:ERβ expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Early Postmenopausal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Postmenopausal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
    <arm_group_label>Early Postmenopausal</arm_group_label>
    <arm_group_label>Late Postmenopausal</arm_group_label>
    <other_name>Climara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 45-70 yr&#xD;
&#xD;
          -  postmenopausal (no menses ≥12 mo or bilateral oophorectomy and FSH &gt;30 IU/L)&#xD;
&#xD;
          -  ≤6yrs or ≥10yrs of menopause (last menses or oophorectomy)&#xD;
&#xD;
          -  BMI &lt;30 kg/m2 and weight stable (±2kg in past 2mo)&#xD;
&#xD;
          -  non-smokers&#xD;
&#xD;
          -  sedentary to moderately active (&lt;3 days/wk of structured exercise)&#xD;
&#xD;
          -  naïve to estrogen-based hormone therapies (previous use ≤6 months)&#xD;
&#xD;
          -  CBC, CMP and TSH values within normal ranges specified by lab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  underwent a partial hysterectomy (i.e., one or both ovaries left intact)&#xD;
&#xD;
          -  underwent menopause (natural, chemical, or surgical) prior to age 45yr&#xD;
&#xD;
          -  are between &gt;6yr and &lt;10yr of menopause (last menses or oophorectomy)&#xD;
&#xD;
          -  previously used (&gt;6 mo) or are currently using any formulation of estrogen-based HT&#xD;
             (e.g., oral Premarin, transdermal 17beta-estradiol, selective estrogen receptor&#xD;
             modulators)&#xD;
&#xD;
          -  have T2DM or are being treated with glucose-lowering/ insulin sensitizing medications&#xD;
&#xD;
          -  have uncontrolled hypertension (SBP&gt;140 and/or DBP&gt;90 mmHg)&#xD;
&#xD;
          -  have hypertriglyceridemia (&gt;400 mg/dL)&#xD;
&#xD;
          -  have contraindications to estrogen therapy (history of venous thromboembolism, heart&#xD;
             disease, myocardial infarction, hormone sensitive cancer)&#xD;
&#xD;
          -  have contraindications to biopsies (severe anemia, blood clotting disorders)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachael E Van Pelt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://medschool.ucdenver.edu/image</url>
    <description>IMAGE research group study website</description>
  </link>
  <reference>
    <citation>Van Pelt RE, Schwartz RS, Kohrt WM. Insulin secretion and clearance after subacute estradiol administration in postmenopausal women. J Clin Endocrinol Metab. 2008 Feb;93(2):484-90. Epub 2007 Nov 6.</citation>
    <PMID>17986638</PMID>
  </reference>
  <reference>
    <citation>Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003 Jan 7;138(1):1-9.</citation>
    <PMID>12513038</PMID>
  </reference>
  <reference>
    <citation>Bonds DE, Lasser N, Qi L, Brzyski R, Caan B, Heiss G, Limacher MC, Liu JH, Mason E, Oberman A, O'Sullivan MJ, Phillips LS, Prineas RJ, Tinker L. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia. 2006 Mar;49(3):459-68. Epub 2006 Jan 27.</citation>
    <PMID>16440209</PMID>
  </reference>
  <reference>
    <citation>Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV; Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004 Jul;47(7):1175-1187. doi: 10.1007/s00125-004-1448-x. Epub 2004 Jul 14.</citation>
    <PMID>15252707</PMID>
  </reference>
  <reference>
    <citation>Pentti K, Tuppurainen MT, Honkanen R, Sandini L, Kröger H, Alhava E, Saarikoski S. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol. 2009 Jun;160(6):979-83. doi: 10.1530/EJE-09-0151. Epub 2009 Mar 25.</citation>
    <PMID>19321660</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <results_first_submitted>September 8, 2020</results_first_submitted>
  <results_first_submitted_qc>February 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2021</results_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>estrogen</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>estrogen receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early Postmenopausal</title>
          <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
        </group>
        <group group_id="P2">
          <title>Late Postmenopausal</title>
          <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Postmenopausal</title>
          <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
        </group>
        <group group_id="B2">
          <title>Late Postmenopausal</title>
          <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>45-70 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp)</title>
        <description>Estrogen mediated change in glucose disposal rate and time since menopause&#xD;
Baseline GDR (no difference between groups)&#xD;
E2 mediated change (significant difference between groups)&#xD;
randomized order of testing, cross-over design</description>
        <time_frame>after 1wk estradiol or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Postmenopausal</title>
            <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
          </group>
          <group group_id="O2">
            <title>Late Postmenopausal</title>
            <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp)</title>
          <description>Estrogen mediated change in glucose disposal rate and time since menopause&#xD;
Baseline GDR (no difference between groups)&#xD;
E2 mediated change (significant difference between groups)&#xD;
randomized order of testing, cross-over design</description>
          <units>mg/kg FFM/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="2.8"/>
                    <measurement group_id="O2" value="11.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="3.1"/>
                    <measurement group_id="O2" value="10.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal Muscle Estrogen Receptor Expression</title>
        <description>Estrogen receptors (ERα and ERβ) differences in time since menopause and estrogen treatment&#xD;
randomized order of testing, cross-over design</description>
        <time_frame>after 1wk estradiol or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Postmenopausal</title>
            <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
          </group>
          <group group_id="O2">
            <title>Late Postmenopausal</title>
            <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Muscle Estrogen Receptor Expression</title>
          <description>Estrogen receptors (ERα and ERβ) differences in time since menopause and estrogen treatment&#xD;
randomized order of testing, cross-over design</description>
          <units>AU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ERα nuclear protein (Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.25"/>
                    <measurement group_id="O2" value="0.71" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERα nuclear protein (Estrogen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.37"/>
                    <measurement group_id="O2" value="0.80" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERβ nuclear protein (Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.35"/>
                    <measurement group_id="O2" value="0.78" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERβ nuclear protein (Estrogen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.47"/>
                    <measurement group_id="O2" value="0.75" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERα cytosolic protein (Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.40"/>
                    <measurement group_id="O2" value="1" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERα cytosolic protein (Estrogen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.32"/>
                    <measurement group_id="O2" value="0.83" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERβ cytosolic protein (Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.41"/>
                    <measurement group_id="O2" value="0.7" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERβ cytosolic protein (Estrogen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.44"/>
                    <measurement group_id="O2" value="0.64" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal Muscle Estrogen Receptor Expression (Protein/Cyto Protein)</title>
        <description>Estrogen receptors (ERα and ERβ) differences in time since menopause and estrogen treatment&#xD;
randomized order of testing, cross-over design</description>
        <time_frame>after 1wk estradiol or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Postmenopausal</title>
            <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
          </group>
          <group group_id="O2">
            <title>Late Postmenopausal</title>
            <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy&#xD;
Estradiol: 1 week of transdermal estradiol (0.15mg)&#xD;
1 week of transdermal placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Muscle Estrogen Receptor Expression (Protein/Cyto Protein)</title>
          <description>Estrogen receptors (ERα and ERβ) differences in time since menopause and estrogen treatment&#xD;
randomized order of testing, cross-over design</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ERα nuclear protein/cyto protein (Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.34"/>
                    <measurement group_id="O2" value="0.78" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERα nuclear protein/cyto protein (Estrogen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.92"/>
                    <measurement group_id="O2" value="0.98" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERβ nuclear protein/cyto protein (Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.53"/>
                    <measurement group_id="O2" value="1.13" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERβ nuclear protein/cyto protein (Estrogen)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.54"/>
                    <measurement group_id="O2" value="1.07" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Estrogen Receptor Expression</title>
        <description>Adipose tissue estrogen receptor expression associated with age and menopause&#xD;
Abdominal and femoral subcutaneous adipose tissue ERα and ERβ expression</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Postmenopausal</title>
            <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy</description>
          </group>
          <group group_id="O2">
            <title>Late Postmenopausal</title>
            <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Estrogen Receptor Expression</title>
          <description>Adipose tissue estrogen receptor expression associated with age and menopause&#xD;
Abdominal and femoral subcutaneous adipose tissue ERα and ERβ expression</description>
          <units>2ΔCT</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal ERα (ESR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="1.17"/>
                    <measurement group_id="O2" value="0.96" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal ERβ (ESR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.70"/>
                    <measurement group_id="O2" value="1.22" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral ERα (ESR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.98"/>
                    <measurement group_id="O2" value="0.97" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral ERβ (ESR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.68"/>
                    <measurement group_id="O2" value="1.25" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adipose Tissue Estrogen Receptor Expression (ERα:ERβ)</title>
        <description>Adipose tissue estrogen receptor expression associated with age and menopause&#xD;
Abdominal and femoral subcutaneous adipose tissue ratio of ERα:ERβ expression</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Postmenopausal</title>
            <description>Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy</description>
          </group>
          <group group_id="O2">
            <title>Late Postmenopausal</title>
            <description>Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Estrogen Receptor Expression (ERα:ERβ)</title>
          <description>Adipose tissue estrogen receptor expression associated with age and menopause&#xD;
Abdominal and femoral subcutaneous adipose tissue ratio of ERα:ERβ expression</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal ERα:ERβ (ESR1:ESR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.71"/>
                    <measurement group_id="O2" value="0.89" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral ERα:ERβ (ESR1:ESR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.143" spread="0.85"/>
                    <measurement group_id="O2" value="0.87" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months participants were randomized in a crossover manner, visits were separated by approximately 2 months. - 1 week of placebo/study testing - 1 week of transdermal E2/study testing.</time_frame>
      <desc>No deaths or serious adverse events occurred in this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>1 week of transdermal placebo</description>
        </group>
        <group group_id="E2">
          <title>Estrogen</title>
          <description>Estradiol: 1 week of transdermal estradiol (0.15mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine/nausea</sub_title>
                <description>Migraine/nausea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Irritation at IV site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Extended E2 administration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Low pulse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CT scan abnormality</sub_title>
                <description>Incidental finding at baseline, not related to the study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bruising/discomfort</sub_title>
                <description>Bruising/discomfort at biopsy site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>IV infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Cox-York</name_or_title>
      <organization>University of Colorado Denver, Anschutz Medical Campus</organization>
      <email>KIMBERLY.COX-YORK@CUANSCHUTZ.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

